Current news and events

Kyrre Emblem among the three research talents honoured by the Norwegian Research Council

Kyrre Eeg Emblem
Kyrre Eeg Emblem

One of The Norwegian Research Council's three new prizes for young outstanding researchers goes to Kyrre Eeg Emblem from the Department of Diagnostic Physics at the Division of Radiology and Nuclear Medicine. Each prize is 500.000 kroner and will be distributed on March 1st.

Kyrre Eeg Emblem's research will benefit cancer patients directly. Using MRI machines, he can predict how different therapies work on people with cancer. The goal is to understand how the treatment affects the disease, and thereby predict which patients respond to the cancer treatment.

 

Nature Communications publication:A human endothelial cell-based recycling assay for screening of FcRn targeted molecules

The HERA-team. Larger photo and caption under "More"
The HERA-team. Larger photo and caption under "More"

In a study published in Nature Communications on February 12th, establishment of a novel in vitro cellular assay is reported, which can be used to gain in-depth insights into how antibodies and albumin variants are transported in and out of cells, and to predict how efficiently such molecules are rescued from intracellular degradation. The assay has been coined HERA and stands for human endothelial cell-based recycling assay.

The study is based on research conducted by scientists from the Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at OUH and UiO, together with several international collaborators from Harvard Medical School, The Jackson Laboratory and Roche Pharma Research and Early Development in Munich.

 

Selected latest original OUH articles

Criterion: journal impact factor > 7, and first or last author from Oslo University Hospital

Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikstrom KI, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ (2018)
Complete Remission with Reduction of High-risk Clones following Haploidentical NK Cell Therapy against MDS and AML
Clin Cancer Res (in press)
PubMed 29444931

Greer M, Berastegui C, Jaksch P, Benden C, Aubert J, Roux A, Lhuillier E, Hirschi S, Reynaud-Gaubert M, Philit F, Claustre J, LePalud P, Stern M, Knoop C, Vos R, Verschuuren E, Fisher A, Riise G, Hansson L, Iversen M, Hämmäinen P, Wedel H, Smits J, Gottlieb J, Holm AM (2018)
Lung transplantation after allogeneic stem cell transplantation: a pan-European experience
Eur Respir J, 51 (2)
PubMed 29444913


More selected publications

 

Ole Jacob Elle appointed "Innovator of the Month" by "Helse Sør-Øst"

Ole Jacob Elle
Ole Jacob Elle

Ole Jacob Elle, head of the "Medical Robotics, visualisation and navigation" research group at The Intervention Centre at the Divsion of Emergencies and Critical Care has been selected as "Innovator of the Month" by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). 
Elle's research activities and interests are presented in a popular science article (in Norwegian) entitled "Technology and health - hand in hand". He is fascinated by robots, holograms and navigation systems, and how these things can make everyday life in health care better.

 

Substantial grant from HELSEVEL to Jon Michael Gran

Jon Michael Gran
Jon Michael Gran

Jon Michael Gran, researcher at the Oslo Centre for Biostatistics and Epidemiology (OCBE), recently received a grant of 15 million NOK from the Research Council of Norway (HELSEVEL program). The title of the project is “Effects of workplace initiatives on sick leave and work participation - new statistical and causal models to utilise population registries”. The project will utilise large linked population-wide registry data in assessing the effects of the Norwegian Agreement on a More Inclusive Working Life (the IA Agreement) and the use of graded sick leave on long-term health related absence from work. 

 

Interdepartmental collaboration cuts drug costs on expensive antibodies for treating eye diseases

The Eye-team (larger photo with caption identifying Eye team members under "More")
The Eye-team (larger photo with caption identifying Eye team members under "More")

Since their introduction 12 years ago, intravitreal anti-vascular endothelial growth factor (VEGF) drugs have gradually become the standard of care for several prevalent and debilitating retinal eye diseases. The anti-VEGF treatment is given by an injection into the eye.  In a ground-breaking project, clinicians, researchers and pharmacists at Oslo University Hospital (OUH) and University of Oslo (UiO) have collaborated to improve the safety, efficacy and economy of the anti-VEGF procedure, which in 2017 was performed about 23.000 times at OUH alone. The results are likely to impact practices across Norway and also internationally.

 

Leiv Arne Rosseland "Researcher of the Month" for January 2018

Leiv Arne Rosseland from the Division of Emergencies and Critical Care was appointed "Researcher of the Month" for January 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). Rosseland works within the field of pain relief, especially related to obstretic anasthesia. He is also concerned that we use the good registry data that we have more actively than today.
Rosseland's work is presented in a feature article published on the home page of Helse Sør-Øst.

 

Karl-Johan Malmberg awarded FRIPRO Toppforsk grant

Karl-J. Malmberg
Karl-J. Malmberg
Karl-Johan Malmberg, head of the "Natural Killer Cell Biology and Cell Therapy" group at the Department of Cancer Immunology, has recently been awarded a prestigious “FRIPRO Toppforsk” grant from the Research Council for the project "Programming natural killer cell function through the organelle communication". 

The Norwegian government is aiming for long-term efforts to build research communities on the highest level. In total 24 Norwegian projects, all disciplines included, receive between 15 and 25 mill NOK. The grants are aimed at research communities that have the potential to become international leaders within their fields.

Two of the 24 selected projects are led by group leaders at the Institute for Cancer Research. The other is Tor Erik Rusten from the Department of Molecular Cell Biology.

 

Prestigious grant to Tor Erik Rusten

Tor Erik Rusten
Tor Erik Rusten

As one of 24 PIs in Norway (all disciplines included), Tor Erik Rusten, who is group leader at Institute for Cancer Research and PI in Centre for Cancer Cell Reprogramming (CanCell), has been awarded a prestigious “Toppforsk” grant from the Research Council for the project “Tumor-Host Biology”.

Each of the 24 projects receive between 15 and 25 mill NOK. The grants are aimed at research communities that have the potential to become international leaders within their fields.

Two of the 24 selected projects are led by group leaders at the Institute for Cancer Research. The other is Karl-Erik Malmberg from the Department of Cancer Immunology.

 

Karl-Johan Malmberg interviewed by NRK on the potential of killer cell research in cancer treatment

Karl-Johan Malmberg (photo: NRK)
Karl-Johan Malmberg (photo: NRK)

Professor Karl-Johan Malmberg, head of the c at the Department of Cancer Immunology at the Institute for Cancer research, was recently interviewed on radio by the Norwegian Broadcasting Corporation (NRK) in connection with a news item on NRK radio and on their home page about recent research progress on the subject "how killer cells may overcome cancer" (entitled "Drepeceller kan ta knekken på kreft").